Enduring Home


Psoriatic arthritis (PsA) is a chronic, progressive arthropathy with heterogeneous clinical presentations. Between 40% and 60% of patients develop erosive and deforming joint complications and pain, impacting their mobility, productivity and physical and psychosocial health-related quality of life.

Current treatment goals for PsA aim to relieve pain, preserve joint structure, improve physical activity and reduce mortality. Conventional treatment options include nonsteroidal anti-inflammatory drugs, intra-articular steroid injections and disease-modifying anti-rheumatic drugs. As the number and diversity of effective targeted treatment options for PsA continue to increase, so do opportunities and challenges in choosing the appropriate therapeutic approach for each individual patient.

To address current clinical challenges, the Warren Alpert Medical School of Brown University, Office of Continuing Medical Education and Catamount Medical Education have developed PATIENTGPS™: Clinical Paths in the Diagnosis and Personalized Treatment of Psoriatic Arthritis.

As a follow up to the successful live meeting series, you can now participate in an interactive online learning activity by clicking the button below.

Click here to download activity slides
Downloadable Slides


CME Information

Activity Release Date: December 8, 2017
Activity Expiration Date: December 8, 2018
Estimated Time to Complete Activity: 1 hour
Media: Internet

Faculty

Robin K. Dore, MD
Clinical Professor of Medicine
David Geffen School of Medicine, UCLA
Los Angeles, CA
Private Practice Rheumatology
Tustin, CA

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the clinical features and symptoms of PsA to support appropriate diagnosis and assessment of disease severity
  • Integrate available diagnostic tests into the diagnostic decision-making process
  • Discuss the significant burden of PsA and its impact on a patient’s quality of life (QOL)
  • Identify current unmet needs in the management of PsA
  • Review recent data on current and emerging targeted PsA therapies
  • Evaluate opportunities for personalization of care for PsA patients with current and emerging therapies

Target Audience
Rheumatologists, dermatologists and other healthcare professionals who manage patients with PsA.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Warren Alpert Medical School of Brown University and Catamount Medical Education. The Warren Alpert Medical School of Brown University is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
The Warren Alpert Medical School of Brown University designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support Acknowledgment
This activity is supported by independent educational grants from Celgene Corporation and Novartis Pharmaceuticals Corporation.

Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. During the period that the activity is available for credit, participants must 1) read the CME information; 2) complete the pre-test (optional), 3) view the entire video and answer questions; and 4) complete the post-test and the evaluation form.

A score of at least 4 out of 6 questions correct must be achieved on the post-test to successfully complete the activity. If you do not receive a passing score, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful. Following the post-test and evaluation form your certificate will be made available immediately. Click on the button labeled “Submit Answers and Get Certificate” in order to have your CME/CNE certificate emailed to you for your records.

Technical Requirements
This activity is best viewed using the most recent versions of Internet Explorer, Google Chrome or Firefox. For interactive content, a broadband connection is required. For all CME/CNE activities featuring audio you must have a sound card and speakers.

Our activities may require JavaScript to be enabled on your computer.

Faculty, Planners and Activity Staff Disclosures
In accordance with the disclosure policy of the Warren Alpert Medical School of Brown University as well as standards set forth by the Accreditation Council for Continuing Medical Education, all CME activity speakers and planners have disclosed all relevant commercial financial relationships received within the past twelve months. This activity’s disclosures have been reviewed and all identified conflicts of interest, if applicable, have been resolved.

The following individuals involved in the development of this activity have indicated they have relationships with industry to disclose relative to the content of this CE activity:

Faculty
Robin K. Dore, MD
Discloses she has been on speakers bureau for Amgen, Novartis, Celgene and AbbVie. She has been a consultant and received grant/research support from Amgen, Novartis, Celgene and AbbVie.

Planners and Independent Reviewers
Alice B. Gottlieb, MD, PhD
Consultant and served on an Advisory Board for Amgen, Astellas, Akros, Centocor (Janssen), Inc.; Celgene, Bristol Myers Squibb Co., Beiersdorf, Inc., Abbott Labs (AbbVie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd., Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, Glaxo Smith Kline, Xenoport, Catabasis, Meiji Seika Pharma Co., Takeda, Mitsubishi, Tanabe Pharma Development America, Inc, Genentech, Baxalta, Kineta One, KPI Therapeutics, Crescendo Bioscience, Aclaris, Amicus, Reddy Labs, Valeant and Dermira. She has received research and educational grant support (paid to Tufts Medical Center until 5/11/16) from Centocor (Janssen), Amgen, Abbott (AbbVie), Novartis, Celgene, Pfizer, Lilly, Levia, Merck, Xenoport, Dermira and Baxalta.

Maria Sullivan, CME Director, Brown University: no relevant financial relationships reported
Susan Denner MD, MS, Medical Director, Catamount Medical Education: no relevant financial relationships reported
Jennifer Green, Chief Learning Officer, Catamount Medical Education: no relevant financial relationships reported
Mary Kay Lavy, Project Manager, Catamount Medical Education: no relevant financial relationships reported

Privacy Policy
The Warren Alpert Medical School Office of CME and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CME credit. This information is provided to activity collaborators for the purposes of CME recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information

For each visitor to this Web site, our Web server automatically recognizes information such as the visitor’s IP address. Catamount Medical Education, LLC, safeguards against the loss, misuse or alteration of information that we have collected in this activity.

Contact Information
If you have questions about this CME/CNE activity, please contact Catamount Medical Education, LLC, at info@catmeded.com or at 860-661-4157.

 

This CME activity is jointly provided by Brown University and Catamount Medical Education.